SCHEMBL6149211

SCHEMBL6149211

Nc1cccc(Cl)c1[C]=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.48
ALDH1A1 P00352 5/20 0.46
NR4A2 P43354 2/20 0.46
CYP3A4 P08684 3/20 0.39
PIK3CA P42336 1/20 0.39
TDP1 Q9NUW8 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2A6 P11509 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
HTR3E A5X5Y0 1/20 0.34
HTR3B O95264 1/20 0.34
HTR3A P46098 1/20 0.34
HTR3D Q70Z44 1/20 0.34
HTR3C Q8WXA8 1/20 0.34
JAK1 P23458 1/20 0.34
LMNA P02545 2/20 0.33
ALOX15 P16050 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL96213 0.83 CYP1A2 (0.43) TSHRALDH1A1NR4A2TDP1CYP1A2
SCHEMBL164718 0.77 TSHR (0.48) TSHRALDH1A1NR4A2CYP3A4PIK3CA
SCHEMBL29555850 0.77 TSHR (0.48) TSHRALDH1A1NR4A2CYP3A4PIK3CA
SCHEMBL910072 0.77 ALDH1A1 (0.41) TSHRALDH1A1CYP3A4PIK3CATDP1
SCHEMBL10885088 0.74 CYP3A4 (0.36) TSHRALDH1A1CYP3A4PIK3CATDP1
SCHEMBL102469 0.74 CYP1A2 (0.36) TSHRALDH1A1TDP1CYP1A2CYP2A6
SCHEMBL20237221 0.73 C1R (0.35) TSHRALDH1A1TDP1CYP1A2CYP2A6
SCHEMBL6151711 0.73 CYP3A4 (0.35) TSHRALDH1A1CYP3A4PIK3CATDP1
SCHEMBL535572 0.73 TAAR1 (0.41) ALDH1A1TDP1CYP1A2CYP2A6HPGD
SCHEMBL6149952 0.73 CD44 (0.50) TSHRALDH1A1CYP3A4PIK3CATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1494700-A2 CASPASE INHIBITORS FOR THE TREATMENT OF DISEASES AND CONDITIONS CAUSED BY EXPOSURE TO RADIONUCLIDES, BIOLOGICAL AGENTS, OR CHEMICAL AGENTS Cytovia, Inc. (US) 2005-01-12 EP claimed
WO-2004002401-A2 CASPASE INHIBITORS FOR THE TREATMENT OF DISEASES AND CONDITIONS CAUSED BY EXPOSURE TO RADIONUCLIDES, BIOLOGICAL AGENTS, OR CHEMICAL AGENTS CYTOVIA, INC. (US) 2004-01-08 WO claimed
EP-1494700-A2 CASPASE INHIBITORS FOR THE TREATMENT OF DISEASES AND CONDITIONS CAUSED BY EXPOSURE TO RADIONUCLIDES, BIOLOGICAL AGENTS, OR CHEMICAL AGENTS Cytovia, Inc. (US) 2005-01-12 EP disclosed
WO-2004002401-A2 CASPASE INHIBITORS FOR THE TREATMENT OF DISEASES AND CONDITIONS CAUSED BY EXPOSURE TO RADIONUCLIDES, BIOLOGICAL AGENTS, OR CHEMICAL AGENTS CYTOVIA, INC. (US) 2004-01-08 WO disclosed